

April 30, 2026

<p>To The Secretary, Listing Department, BSE Limited, 1st Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400001.</p> <p>Scrip Code: 540975</p>	<p>To The Manager, Listing Department, The National Stock Exchange of India Ltd, Bandra Kurla Complex, Bandra (East), Mumbai 400051.</p> <p>Scrip Symbol: ASTERDM</p>
--	--

Dear Sir / Madam,

Subject: Outcome of the meeting of the Board of Directors held on Thursday, April 30, 2026

Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the subject captioned, we wish to inform you that the Board of Directors at its meeting held on **Thursday, April 30 2026**, inter alia, considered and approved the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2026, together with the Auditor's Report thereon.

We would like to declare that Deloitte Haskins & Sells, the Statutory Auditors, have issued their auditors' report with an unmodified opinion.

A copy of the said results along with the Auditors' Report thereon are enclosed herewith and the same are being uploaded on the website of the Company at www.asterdmhealthcare.in

The Meeting of the Board of Directors commenced at 10:30 AM (IST) and concluded at 03:35 PM (IST).

Kindly take the above on records.

Thank you,

Yours faithfully,
For **Aster DM Healthcare Limited**

Hemish Purushottam

Company Secretary and Compliance Officer
M. No: A24331

Aster DM Healthcare Limited - Registered Office

No 7-1-450/20, Plot No-04, Mythri Vihar,
Sanjeev Reddy Nagar, Hyderabad, Ameerpet,
Telangana, India - 500038

Aster DM Healthcare Limited - Corporate Office

Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1,
Mission Road, Sampangi Rama Nagar, Bengaluru,
Karnataka, India - 560027

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ASTER DM HEALTHCARE LIMITED

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended 31 March 2026 and (b) reviewed the Standalone Financial Results for the quarter ended 31 March 2026 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended 31 March 2026" of **Aster DM Healthcare Limited** (the "Company"), which includes financial statements of DM Healthcare Employees Welfare Trust (the "ESOP trust") (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit report of the ESOP trust auditor as referred to in Other Matters section below the Standalone Financial Results for the year ended 31 March 2026:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended 31 March 2026

With respect to the Standalone Financial Results for the quarter ended 31 March 2026, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review report of the ESOP trust auditor as referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended 31 March 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Deloitte Haskins & Sells

Basis for Opinion on the Audited Standalone Financial Results for the year ended 31 March 2026

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended 31 March 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the ESOP trust auditor in terms of their report referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended 31 March 2026 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended 31 March 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended 31 March 2026

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended 31 March 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Deloitte Haskins & Sells

- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company and the ESOP trust to express an opinion on the Annual Standalone Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities or business activities included in the Annual Standalone Financial Results of which we are the independent auditors. For the other entity or business activity included in the Annual Standalone Financial Results, which has been audited by the ESOP trust auditor, such ESOP trust auditor remains responsible for the direction, supervision and performance of the audit carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended 31 March 2026

We conducted our review of the Standalone Financial Results for the quarter ended 31 March 2026 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Deloitte Haskins & Sells

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- The Statement includes the results for the Quarter ended 31 March 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.
- We did not audit the financial statements of ESOP trust included in the Statement, whose financial statements reflect total assets of INR 19.57 crores (before elimination) as at 31 March 2026 and total revenues of INR 0.20 crore and INR 0.80 crores for the quarter and year ended 31 March 2026 respectively, total net profit after tax of INR 0.21 crores and INR 0.65 crores for the quarter and year ended 31 March 2026 respectively and other comprehensive income of Nil and Nil for the quarter and year ended 31 March 2026, respectively, and net cash outflow of INR 12.60 crores for the year ended 31 March 2026 as considered in the Statement. The financial statement of the ESOP trust have been audited/ reviewed, as applicable, by the ESOP trust auditor whose report have been furnished to us, and our opinion and conclusion in so far as it relates to the amounts and disclosures included in respect of such ESOP trust, is based solely on the report of such ESOP trust auditor and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our report on the statement is not modified in respect of above matters.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008072S)

**ANKIT
DAGA** Digitally signed
by ANKIT DAGA
Date: 2026.04.30
15:36:17 +05'30'

Ankit Daga
Partner
(Membership No.512486)
(UDIN: 26512486BEZAUS6493)

Place: Bengaluru
Date: 30 April 2026

Aster DM Healthcare Limited
CIN : L85110TS2008PLC207383

Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Standalone Financial Results for the quarter and year ended 31 March 2026

(Amount in INR crores)

Particulars	Quarter ended			Year ended	
	31 March 2026 (refer Note 8)	31 December 2025	31 March 2025 (refer Note 8)	31 March 2026	31 March 2025
	(Unaudited)			(Audited)	
1 Income					
Revenue from operations	655.10	665.75	573.86	2,615.70	2,320.48
Other income	40.55	31.41	35.13	155.03	5,738.67
Total income	695.65	697.16	608.99	2,770.73	8,059.15
2 Expenses					
Purchase of medicines and medical consumables	122.14	136.94	112.80	530.68	455.49
Changes in inventories	8.15	0.43	3.30	8.49	1.82
Professional fees to consultant doctors	149.99	149.94	132.86	579.85	525.83
Laboratory outsourcing charges	18.98	20.70	16.93	78.55	73.87
Employee benefits expense	103.94	105.10	86.06	403.45	375.09
Finance costs	20.98	22.11	23.25	87.27	85.57
Depreciation and amortisation expenses	37.57	39.45	37.76	154.02	144.52
Other expenses	113.53	123.95	107.01	464.30	431.86
Total expenses	575.28	598.62	519.97	2,306.61	2,094.05
3 Profit before exceptional items and tax (1-2)	120.37	98.54	89.02	464.12	5,965.10
4 Exceptional items (refer Notes 6)	(77.73)	(7.44)	(26.42)	(89.92)	323.15
5 Profit before tax (3+4)	42.64	91.10	62.60	374.20	6,288.25
6 Tax expenses					
Current tax	19.93	45.80	12.00	124.37	74.82
Deferred tax	(4.75)	(9.86)	(10.47)	(17.99)	4.46
Total tax expense	15.18	35.94	1.53	106.38	79.28
7 Profit for the period / year (5-6)	27.46	55.16	61.07	267.82	6,208.97
8 Other comprehensive income/(loss) for the period / year					
<i>Items that will not be reclassified subsequently to profit or loss</i>					
Remeasurement of net defined benefit liability	1.18	(1.39)	(1.38)	(0.21)	(1.38)
Income tax relating to items that will not be reclassified to profit or loss	(0.30)	0.35	0.35	0.05	0.35
Other comprehensive income/(loss), net of taxes	0.88	(1.04)	(1.03)	(0.16)	(1.03)
9 Total comprehensive income (7+8)	28.34	54.12	60.04	267.66	6,207.94
10 Paid-up equity share capital (Face value of INR 10 each)	518.13	518.13	499.52	518.13	499.52
11 Other equity				3,848.09	2,839.97
12 Earnings per share (Face value of INR 10 each)					
Basic (in INR)	Not annualised	Not annualised	Not annualised	Annualised	Annualised
Diluted (in INR)	0.53	1.07	1.23	5.20	124.67
	0.53	1.07	1.22	5.19	124.52

See accompanying notes to the Statement of Standalone Financial Results

Aster DM Healthcare Limited
CIN : L85110TS2008PLC207383

Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Standalone Balance Sheet as at 31 March 2026

(Amount in INR crores)

Particulars		As at	
		31 March 2026	31 March 2025
		(Audited)	
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	1,051.39	1,021.20
	Right-of-use assets	918.91	737.99
	Capital work-in-progress	160.08	55.41
	Other intangible assets	2.08	1.25
	Financial assets		
	Investments	2,215.67	1,008.96
	Loans	279.59	316.12
	Other financial assets	124.88	110.13
	Income tax assets	43.93	76.41
	Other non-current assets	32.88	25.67
	Total non-current assets	4,829.41	3,353.14
2	Current assets		
	Inventories	33.24	41.73
	Financial assets		
	Trade receivables	178.94	138.13
	Cash and cash equivalents	119.44	119.84
	Bank balances other than cash and cash equivalents above	1,006.09	1,168.87
	Other financial assets	139.29	117.97
	Other current assets	33.63	25.08
	Total current assets	1,510.63	1,611.62
	TOTAL ASSETS	6,340.04	4,964.76
B	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	518.13	499.52
	Other equity	3,848.09	2,839.97
	Total equity	4,366.22	3,339.49
2	Liabilities		
2(a)	Non-current liabilities		
	Financial liabilities		
	Borrowings	239.94	298.46
	Lease liabilities	1,014.11	806.10
	Deferred tax liabilities (net)	30.92	48.96
	Other non-current liabilities	37.88	35.96
	Provisions	19.76	14.91
	Total non-current liabilities	1,342.61	1,204.39
2(b)	Current liabilities		
	Financial liabilities		
	Borrowings	73.74	78.92
	Lease liabilities	19.07	16.48
	Trade payables		
	- Total outstanding dues of micro and small enterprises	21.66	9.52
	- Total outstanding dues of creditors other than micro and small enterprises	270.68	238.39
	Other financial liabilities	205.52	35.28
	Other current liabilities	35.75	40.72
	Provisions	4.79	1.57
	Total current liabilities	631.21	420.88
	TOTAL EQUITY AND LIABILITIES	6,340.04	4,964.76

See accompanying notes to the Statement of Standalone Financial Results

Aster DM Healthcare Limited
CIN : L85110TS2008PLC207383

Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Standalone Cash Flows for the year ended 31 March 2026

(Amount in INR crores)

Particulars	For the year ended	For the year ended
	31 March 2026	31 March 2025
	(Audited)	
Cash flows from operating activities		
Profit before tax for the year	374.20	6,288.25
<i>Adjustments for non cash and non operating items :</i>		
Depreciation and amortisation expenses	154.02	144.52
Finance costs	87.27	85.57
Dividend income on non-current investments	(11.95)	(5,577.90)
Profit on sale of investment	-	(381.12)
Interest income and other non-operating income	(124.38)	(139.80)
Allowances for credit losses on financial assets	7.96	9.68
Equity settled share based payment	8.31	8.42
Impact of lease modification	-	(7.22)
Loss on sale of property, plant and equipment (net)	1.19	0.41
Provision for diminution in value of investments	57.24	-
Intangible assets under development written off	-	0.15
Operating cash flows before movements in working capital	553.86	430.96
Working capital adjustments :		
Changes in trade receivables	(48.77)	(20.26)
Changes in inventories	8.49	1.82
Changes in other financial assets	(101.00)	(2.81)
Changes in other assets	(14.03)	(0.46)
Changes in trade payables	44.43	23.39
Changes in provisions	8.28	2.81
Changes in other financial liabilities	25.08	(11.74)
Changes in other liabilities	2.78	9.97
Cash generated from operating activities	479.12	433.68
Taxes paid, net of refund received	(91.99)	(66.45)
Net cash generated from operating activities (A)	387.13	367.23
Cash flows from investing activities		
Movement in other bank balances and restricted deposits	164.19	(1,161.74)
Redemption of/(Investment in) subsidiaries and associates (net)	(179.21)	1,759.14
(Investments in)/proceeds from sale of mutual funds (net)	-	8.42
Interest received	70.36	58.06
Dividend received	11.95	5,577.90
Payment to acquire intangible assets	(2.27)	(0.56)
Payment to acquire property, plant and equipment (including capital work-in-progress)	(153.84)	(138.31)
Loan to subsidiary and associate (net of loan repayment)	(55.86)	(81.02)
Proceeds on sale of property, plant and equipment	1.09	1.11
Net cash generated from / (used in) investing activities (B)	(143.59)	6,023.00
Cash flows from financing activities		
Payment of lease liabilities	(88.78)	(80.41)
Finance cost paid	(32.63)	(37.83)
Dividend paid	(51.87)	(6,173.59)
Proceeds from exercise of share options	2.50	3.09
Long term secured loans availed	6.46	125.02
Long term secured loans repaid	(79.62)	(65.39)
Current borrowings (repaid)/availed, net	-	(69.00)
Net cash used in financing activities (C)	(243.94)	(6,298.11)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(0.40)	92.12
Cash and cash equivalents at the beginning of the year	119.84	27.72
Cash and cash equivalents at the end of the year	119.44	119.84

Components of cash and cash equivalents

Particulars	For the year ended	For the year ended
	31 March 2026	31 March 2025
Cash and cash equivalents comprises of :		
a) Cash on hand	1.04	1.68
b) Balance with banks	118.37	118.11
c) Cash /Cheques- in transit	0.03	0.05
Total	119.44	119.84

Changes in liabilities arising from financing activities for the year ended 31 March 2026

Particulars	As at		Movement during the year		Finance costs	As at
	01 April 2025	Cash inflows	Cash outflows	Additions/ Modifications		
Borrowings (Current and Non-current) including interest	377.66	6.46	(112.25)	-	9.06	313.84
Lease liabilities	822.58	-	(88.78)	228.22	16.80	1,033.18
Total	1,200.24	6.46	(201.03)	228.22	25.86	1,347.02

Changes in liabilities arising from financing activities for the year ended 31 March 2025

Particulars	As at		Movement during the year		Finance costs	As at
	01 April 2024	Cash inflows	Cash outflows	Additions/ Modifications		
Borrowings (Current and Non-current) including interest	387.16	125.02	(172.22)	-	1.93	377.66
Lease liabilities	454.69	-	(80.41)	384.40	14.10	822.58
Total	841.85	125.02	(252.63)	384.40	16.03	1,200.24

Note : The above Statement of audited Standalone Cash Flows has been prepared under the 'Indirect method' as set out in Ind AS 7, 'Statement of Cash Flows'.

Aster DM Healthcare Limited

CIN : L85110TS2008PLC207383

Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Notes to the Statement of Standalone Financial Results:

- 1) The Statement of Standalone Financial Results of Aster DM Healthcare Limited ('the Company'), which includes the financial information of DM Healthcare Employees Welfare Trust (the 'ESOP Trust'), for the quarter and year ended 31 March 2026 ('the Statement') has been reviewed by the Audit Committee on 29 April 2026 and approved by the Board of Directors on 30 April 2026. The statutory auditors, Deloitte Haskins & Sells, have expressed an unmodified review conclusion on the Standalone Financial Results for the quarter ended 31 March 2026 and an unmodified audit opinion on the Standalone Financial Results for the year ended 31 March 2026.
- 2) The Statement has been prepared in accordance with Indian Accounting Standards ('IndAS'), prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.
- 3) In accordance with Ind AS 108, Operating Segments, segment information has been provided in the Statement of Consolidated Financial Results of the Company and therefore no separate disclosure on segment information is given in the Statement of Standalone Financial Results.
- 4) During the year ended 31 March 2026, the Nomination and Remuneration Committee of the Company approved grant of 507,500 options (exercise price ranging from INR 10.00 to INR 514.00) to the employees under the Aster DM Healthcare Limited Employees Stock Option Plan 2013.
- 5) On 11 December 2025, the Company submitted the Scheme of Amalgamation ('Scheme') by way of merger of Quality Care India Limited (Transferor Company/QCIL) with Aster DM Healthcare Limited (Transferee Company) (the 'Applicant Companies') to the National Company Law Tribunal ('NCLT') for approval of the said scheme. Subsequently, on 21 January 2026, the Company received the Order from NCLT for convening the meetings of the Unsecured Trade Creditors and Equity Shareholders of the Applicant Companies during the period 27 February 2026 to 13 March 2026. Pursuant to this, the Company conducted its meetings on 10 March 2026 and obtained approval from the Equity Shareholders and Unsecured Trade Creditors with the requisite majority.
- 6) The Company has presented the below items as Exceptional Items in the Statement :
 - i) The Company concluded the separation of its Gulf Cooperation Council (GCC) business on 3 April 2024. Pursuant to the sale, the Company received a dividend of INR 5,569.96 crores from Affinity Holdings Private Limited ("Affinity"), its subsidiary in Mauritius. Consequent to this, the Company has an obligation to incur CSR expenses amounting to INR 37.13 crores.
 - ii) During the year ended 31 March 2026, the Company carried out a review of the carrying value of all its investments. Based on this review, the recoverable amount of the investment in a subsidiary and an associate was assessed to be lower than its carrying value, primarily due to a decline in performance during the year and lower projected growth rates over the forecast period. Accordingly, the Company recognised loss of INR 57.24 crores due to the reduction in the carrying value of such investments. The total carrying value of the Company's investments in those entities as at the reporting date amounts to INR 225.78 crores.
 - iii) On 21 November 2025, the Government of India notified the four Labour Codes ('the New Labour Codes') - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Company has assessed and disclosed the incremental impact of these changes on the basis of best available information, consistent with the New Labour Codes and the guidance provided by the Institute of Chartered Accountants of India. The incremental impact in the year consists of provision for gratuity amounting to INR 0.86 crores, provision for compensated absences amounting to INR 2.78 crores and provision for overtime allowance amounting to INR 0.50 crores. This is primarily due to revision in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the New Labour Codes and would make appropriate adjustments on the basis of such developments.
 - iv) On 23 April 2018, the Government of Kerala issued an order revising the minimum wages with retrospective effect from 1 October 2017. The Company had filed a writ petition (WP (C) No. 25109/2018) before the Hon'ble High Court of Kerala challenging the retrospective applicability of the order and failure to follow procedure for revision of rate of minimum wages under the Minimum Wages Act. The Hon'ble High Court of Kerala granted an interim stay and the matter is currently pending adjudication. On 6 March 2026, the Government of Kerala published a draft notification with respect to the minimum wages which superseded the old Notification issued in April 2018. Based on the above and legal advice obtained, Management believes that its position is likely to be upheld. Accordingly provision amounting to INR 25.41 crores with respect to above matter has been reversed.
 - v) The Company incurred one-time expenses amounting to INR 16.82 crores towards professional fees relating to the merger, proposed acquisition and such other related costs.
- 7) The Board of Directors at its meeting held on 26 March 2026 approved an interim dividend of INR 3 (par value of INR 10 each) per equity share. The same has been distributed to the shareholders of the Company.
- 8) The figures for the quarter ended 31 March 2026/31 March 2025 are balancing figures between the audited figures in respect of year ended 31 March 2026 / 31 March 2025 and the unaudited published figures in respect of nine months ended 31 December 2025 / 31 December 2024, which was subjected to limited review by the Statutory Auditors.
- 9) Statement of audited Standalone Financial Results are available for perusal at the website of the Company and the stock exchanges.

For and on behalf of the Board of Directors of

Aster DM Healthcare Limited

CIN : L85110TS2008PLC207383

MANDAYAPU
RATH AZAD
MOOPEN

Digitally signed by
MANDAYAPURAT
H AZAD MOOPEN
Date: 2026.04.30
15:26:41 +05'30'

Dr. Azad Moopen

Chairman and Executive Director

DIN 00159403

Dubai

30 April 2026

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ASTER DM HEALTHCARE LIMITED

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended 31 March 2026 and (b) reviewed the Consolidated Financial Results for the quarter ended 31 March 2026 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Consolidated Financial Results for the Quarter and Year Ended 31 March 2026" of **Aster DM Healthcare Limited** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group"), and its share of the net loss after tax and other comprehensive loss of its associates for the quarter and year ended 31 March 2026, which includes the financial statement of DM Healthcare Employees Welfare Trust (the "ESOP trust") ("the Statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit report of the ESOP trust auditor and other auditors on separate financial statements of subsidiaries and associates referred to in Other Matters section below, the Consolidated Financial Results for the year ended 31 March 2026:

- (i) includes the financial results of the entities as provided in Annexure 1;
- (ii) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group, associates and ESOP trust for the year ended 31 March 2026.

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended 31 March 2026

With respect to the Consolidated Financial Results for the quarter ended 31 March 2026, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review report of the ESOP trust auditor and other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended 31 March 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended 31 March 2026

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group, its associates and the ESOP trust in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended 31 March 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the ESOP trust auditor and other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Holding Company's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended 31 March 2026, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended 31 March 2026 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group including its associates and ESOP trust in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.

Deloitte Haskins & Sells

The respective Board of Directors of the companies included in the Group and of its associates and ESOP trust are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its associates and ESOP trust and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and of its associates and ESOP trust are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and ESOP trust are responsible for overseeing the financial reporting process of the Group and of its associates and ESOP trust.

Auditor's Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended 31 March 2026

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended 31 March 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Deloitte Haskins & Sells

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and ESOP trust to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and ESOP trust to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results/ Financial Information of the entities within the Group and its associates and ESOP trust to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the ESOP trust auditor or other auditors, such ESOP trust auditor or other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

Deloitte Haskins & Sells

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended 31 March 2026

We conducted our review of the Consolidated Financial Results for the quarter ended 31 March 2026 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- The Statement includes the results for the quarter ended 31 March 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.
- We did not audit/review the financial statements of the ESOP trust included in the standalone audited financial statements of the Group whose financial statements reflect total assets of INR 19.57 crores (before elimination) as at 31 March 2026 and total revenues of INR 0.20 crores and INR 0.80 crores for the quarter and year ended 31 March 2026 respectively, total net profit after tax of INR 0.21 crores and INR 0.65 crores for the quarter and year ended 31 March 2026 respectively and other comprehensive income of Nil and Nil for the quarter and year ended 31 March 2026 respectively and net cash outflows of INR 12.60 crores for the year ended 31 March 2026, as considered in the standalone audited financial statements of the Group. The financial statements of the ESOP trust have been audited/reviewed, by the ESOP trust auditor whose report has been furnished to us and our opinion and conclusion in so far as it relates to the amounts

Deloitte Haskins & Sells

and disclosures included in respect of ESOP trust is based solely on the report of such ESOP trust auditor and the procedures performed by us as stated under Auditor's Responsibilities section above.

- We did not audit/review the financial statements / financial information of 16 subsidiaries and 2 associates included in the consolidated financial results, whose financial statements / financial information reflect total assets of INR 504.04 crores (before elimination) as at 31 March 2026 and total revenues of INR 50.07 crores and INR 215.04 crores for the quarter and year ended 31 March 2026 respectively, total net loss after tax of INR 6.54 crores and total net loss after tax of INR 28.71 crores for the quarter and year ended 31 March 2026 respectively and other comprehensive loss of INR 0.04 crores for the quarter ended 31 March 2026 and other comprehensive income of INR 0.16 crores for the year ended 31 March 2026 respectively and net cash inflow of INR 1.20 crores for the year ended 31 March 2026, as considered in the Statement. The consolidated financial results also includes the Group's share of total net profit after tax of INR 0.16 crores and INR 0.65 crores for the quarter and year ended 31 March 2026 respectively and other comprehensive income of Nil and Nil for the quarter and year ended 31 March 2026 respectively, as considered in the Statement, in respect of 2 associates, whose financial statements / financial information have not been audited by us. These financial statements / financial information have been audited/ reviewed, as applicable, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No.008072S)

ANKIT
DAGA

Digitally signed by
ANKIT DAGA
Date: 2026.04.30
15:34:53 +05'30'

Ankit Daga
Partner
(Membership No.512486)
(UDIN:26512486EEYDNE2234)

Place: Bengaluru
Date: 30 April 2026

Deloitte Haskins & Sells

Annexure 1 – List of entities included in the Consolidated Financial Results

S.No	Entity	Relationship	Country of incorporation
1	Aster DM Healthcare Limited	Parent	India
2	DM Med City Hospitals (India) Private Limited	Wholly owned Subsidiary	India
3	Ambady Infrastructure Private Limited	Wholly owned Subsidiary	India
4	Aster DM Multispecialty Hospital Private Limited (formerly known as Aster DM Healthcare (Trivandrum) Private Limited)	Wholly owned Subsidiary	India
5	Sri Sainatha Multispecialty Hospitals Private Limited	Wholly owned Subsidiary	India
6	Aster Clinical Lab LLP	Wholly owned Subsidiary	India
7	Aster DM Super-Specialty Hospital (Sarjapur) Private Limited	Wholly owned Subsidiary (w.e.f. 21 July 2025)	India
8	Aster DM Super-Specialty Hospital Private Limited (formerly known as Aster DM Super-Specialty Hospitals (Yeswanthpur) Private Limited)	Wholly owned Subsidiary (w.e.f. 28 July 2025)	India
9	DM Healthcare Employees Welfare Trust	Trust	India
10	Affinity Holdings Private Limited	Wholly owned Subsidiary	Mauritius
11	Malabar Institute of Medical Sciences Limited	Subsidiary	India
12	Dr. Ramesh Cardiac and Multispecialty Hospitals Private Limited	Subsidiary	India
13	Prerana Hospital Limited	Subsidiary	India

Deloitte Haskins & Sells

14	Hindustan Pharma Distributors Private Limited	Subsidiary		India
15	EMED Human Resources India Private Limited	Step Subsidiary	down	India
16	Ezhimala Infrastructure LLP	Step Subsidiary	down	India
17	Warseps Healthcare LLP	Step Subsidiary	down	India
18	Sanghamitra Hospitals Private Limited	Step Subsidiary	down	India
19	Aster Ramesh Duhita LLP	Step Subsidiary	down	India
20	Komali Fertility Centre LLP	Step Subsidiary	down	India
21	Komali Fertility Centre LLP Ongole	Step Subsidiary	down	India
22	Adiran IB Healthcare Private Limited	Step Subsidiary	down	India
23	Cantown Infra Developers LLP	Step Subsidiary	down	India
24	Aasraya Healthcare LLP	Step Subsidiary	down	India
25	MIMS Infrastructure and Properties Private Limited	Associate		India
26	Mindriot Research and Innovation Foundation	Associate		India
27	Alfaone Medicals Private Limited	Associate		India
28	Alfaone Retail Pharmacies Private Limited	Associate		India

Statement of Consolidated Financial Results for the quarter and year ended 31 March 2026

(Amount in INR crores)

Particulars	Quarter ended			Year ended	
	31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
	(Unaudited)			(Audited)	
Continuing operations					
1 Income					
Revenue from operations	1,182.38	1,185.76	1,000.34	4,643.22	4,138.46
Other income	36.20	27.97	31.28	125.60	148.23
Total income	1,218.58	1,213.73	1,031.62	4,768.82	4,286.69
2 Expenses					
Purchase of medicines and medical consumables	258.97	270.44	218.17	1,047.61	920.16
Changes in inventories	4.19	(2.96)	7.06	1.18	18.17
Professional fees to consultant doctors	264.66	270.36	229.98	1,031.87	921.17
Laboratory outsourcing charges	5.35	8.28	6.99	27.52	29.21
Employee benefits expense	219.99	221.37	182.96	848.09	760.39
Finance costs	29.99	31.46	32.43	122.98	123.81
Depreciation and amortisation expenses	67.24	67.67	63.95	264.25	248.84
Other expenses	196.64	207.02	163.11	785.92	724.83
Total expenses	1,047.03	1,073.64	904.65	4,129.42	3,746.58
3 Profit before share of loss of equity accounted investees, exceptional items and tax (1-2)	171.55	140.09	126.97	639.40	540.11
4 Share of loss of equity accounted investees	(8.53)	(8.75)	(10.01)	(37.00)	(18.91)
5 Exceptional items (Refer Note 5)	0.33	(28.29)	(26.42)	(32.71)	(50.14)
6 Profit before tax (3+4+5)	163.35	103.05	90.54	569.69	471.06
7 Tax expense					
Current tax	36.37	59.14	18.01	186.03	125.73
Deferred tax	(26.60)	(14.74)	(13.01)	(43.44)	8.64
Total tax expense	9.77	44.40	5.00	142.59	134.37
8 Profit for the period/ year from continuing operations (6-7)	153.58	58.65	85.54	427.10	336.69
9 Discontinued operations					
(a) Loss before tax from discontinued operations (Refer Note 9)	-	-	-	-	(76.89)
(b) Tax expense of discontinued operations (Refer Note 9)	-	-	-	-	-
(c) Gain on disposal of business operations (Refer Note 9)	-	-	-	-	5,148.09
Profit after tax from discontinued operations (a+b+c)	-	-	-	-	5,071.20
10 Profit for the period/ year (8+9)	153.58	58.65	85.54	427.10	5,407.89
11 Other comprehensive income/ (loss) for the period/ year					
<i>Items that will not be reclassified subsequently to profit or loss</i>					
Remeasurement of net defined benefit liability	2.72	(2.94)	(3.09)	(0.22)	(3.09)
Income tax on items that will not be reclassified subsequently to profit or loss	(0.65)	0.70	0.79	0.05	0.79
<i>Items that will be reclassified subsequently to profit or loss</i>					
Exchange difference in translating financial statements of foreign operations	0.73	0.25	0.37	0.73	0.25
Income tax on items that will be reclassified subsequently to profit or loss	(0.20)	(0.06)	(0.06)	(0.20)	(0.06)
Other comprehensive income/ (loss), net of taxes	2.60	(2.05)	(1.99)	0.36	(2.11)
12 Total comprehensive income (10+11)	156.18	56.60	83.55	427.46	5,405.78
13 Profit attributable to :					
Owners of the Company	140.17	52.45	79.02	388.14	5,377.83
Non-controlling interests	13.41	6.20	6.52	38.96	30.06
Profit for the period/ year	153.58	58.65	85.54	427.10	5,407.89
14 Other comprehensive income/ (loss) attributable to :					
Owners of the Company	2.39	(1.82)	(1.92)	0.38	(2.04)
Non-controlling interests	0.21	(0.23)	(0.07)	(0.02)	(0.07)
Other comprehensive income/ (loss) for the period/ year	2.60	(2.05)	(1.99)	0.36	(2.11)
15 Total comprehensive income attributable to :					
Owners of the Company	142.56	50.63	77.10	388.52	5,375.79
Non-controlling interests	13.62	5.97	6.45	38.94	29.99
Total comprehensive income for the period/ year	156.18	56.60	83.55	427.46	5,405.78
16 Paid-up equity share capital (Face value of INR 10 each)	518.13	518.13	499.52	518.13	499.52
17 Other equity				4,057.73	2,928.55
18 Earnings per share (Face value of INR 10 each) from					
Continuing Operations (INR)					
Basic	2.72	1.02	1.59	7.53	6.16
Diluted	2.71	1.02	1.58	7.52	6.15
Discontinued Operations (INR)					
Basic	-	-	-	-	101.82
Diluted	-	-	-	-	101.70
Continuing & Discontinued Operations (INR)					
Basic	2.72	1.02	1.59	7.53	107.98
Diluted	2.71	1.02	1.58	7.52	107.85

See accompanying notes to the Statement of Consolidated Financial Results

Aster DM Healthcare Limited
CIN : L85110TS2008PLC207383

Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Consolidated Balance Sheet as at 31 March 2026

(Amount in INR crores)

Particulars		As at	
		31 March 2026	31 March 2025
		(Audited)	
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	2,618.74	2,372.54
	Right-of-use assets	1,339.54	1,255.29
	Capital work-in-progress	412.59	290.74
	Goodwill	264.12	264.12
	Other intangible assets	19.25	28.07
	Intangible asset under development	7.02	2.25
	Financial assets		
	Investments	1,165.15	243.69
	Loans	1.25	1.25
	Other financial assets	136.27	84.02
	Income tax assets	73.80	99.62
	Deferred tax assets	36.20	6.21
	Other non-current assets	90.24	57.11
	Total non-current assets	6,164.17	4,704.91
2	Current assets		
	Inventories	91.16	92.35
	Financial assets		
	Investments	1.41	1.42
	Trade receivables	307.23	257.81
	Cash and cash equivalents	228.07	164.59
	Bank balances other than cash and cash equivalents above	1,097.29	1,215.41
	Other financial assets	158.60	116.19
	Other current assets	64.03	53.70
	Total current assets	1,947.79	1,901.47
	TOTAL ASSETS	8,111.96	6,606.38
B	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	518.13	499.52
	Other equity	4,057.73	2,928.55
	Total equity attributable to owners of the Company	4,575.86	3,428.07
2	Non-controlling interests	257.84	223.38
	Total equity	4,833.70	3,651.45
3	Liabilities		
3(a)	Non-current liabilities		
	Financial liabilities		
	Borrowings	558.44	483.71
	Lease liabilities	1,488.83	1,345.59
	Other financial liabilities	3.78	5.95
	Deferred tax liabilities	132.82	146.12
	Other non-current liabilities	61.80	52.57
	Provisions	53.43	41.78
	Total non-current liabilities	2,299.10	2,075.72
3(b)	Current liabilities		
	Financial liabilities		
	Borrowings	142.74	158.47
	Lease liabilities	29.65	30.00
	Trade payables		
	- Total outstanding dues of micro and small enterprises	44.42	19.46
	- Total outstanding dues of creditors other than micro and small enterprises	437.09	406.74
	Other financial liabilities	89.96	188.68
	Income tax liabilities	0.01	0.02
	Other current liabilities	223.23	71.17
	Provisions	12.06	4.67
	Total current liabilities	979.16	879.21
	TOTAL EQUITY AND LIABILITIES	8,111.96	6,606.38

See accompanying notes to the Statement of Consolidated Financial Results

Aster DM Healthcare Limited

CIN : L85110TS2008PLC207383

Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Consolidated Cash Flows for the year ended 31 March 2026

(Amount in INR crores)

Particulars	For the year ended 31 March 2026 (Audited)	For the year ended 31 March 2025 (Audited)
Cash flows from operating activities		
Profit before tax from Continuing Operations	569.69	471.06
Profit before tax from Discontinued Operations	-	5,071.20
<i>Adjustments for</i>		
Depreciation and amortisation expenses	264.25	254.68
Fair value (gain)/loss on derivatives	(1.92)	0.75
Loss on sale of property, plant and equipment	1.88	1.43
Allowance for credit loss on financial assets	12.32	10.03
Profit on sale of investment	(0.01)	(8.46)
Equity settled share based payment	8.31	8.42
Share of loss of equity accounted investees	37.00	18.91
Finance costs	122.98	126.96
Interest and other non operating income	(103.27)	(127.02)
Intangible assets under development written off	-	0.15
Gain on disposal of business operations	-	(5,148.09)
Operating profit before working capital changes	911.23	680.02
<i>Working capital changes</i>		
Changes in inventories	1.19	18.17
Changes in trade receivable	(61.74)	(34.49)
Changes in other financial assets and other assets	(96.02)	(33.16)
Changes in other financial liabilities, trade payables, provisions and other liabilities	61.48	(90.98)
Cash generated from operations	816.14	539.56
Income tax paid, net	(160.22)	(114.51)
Net cash generated from operating activities (A)	655.92	425.05
Cash flows from investing activities		
Acquisition of property, plant and equipment and capital work-in-progress	(469.08)	(346.04)
Acquisition of other intangible assets	(8.44)	(10.69)
Proceeds from disposal of property, plant and equipment	0.70	1.89
Proceeds from sale of discontinued Operations	-	7,563.15
Interest received	67.76	64.42
Redemption of / (Investment) in mutual fund (net)	0.01	8.46
Investments/ loans given to related parties	(3.07)	(73.45)
Movement in other bank balances and restricted deposits	123.91	(1,184.99)
Net cash generated from / (used in) investing activities (B)	(288.21)	6,014.87
Cash flows from financing activities		
Proceeds from exercise of share options	2.50	3.09
Non-current borrowings availed	164.97	188.46
Non-current borrowings repaid	(140.02)	(133.57)
Current borrowings movement, (net)	(10.37)	(83.12)
Lease payments	(131.17)	(114.45)
Acquisition of non-controlling interests	(79.63)	-
Acquisition of subsidiary, net of cash and cash equivalents acquired	(2.31)	13.82
Dividend paid to non-controlling interest	(3.26)	(2.08)
Dividend paid to owners	(51.87)	(6,173.24)
Finance cost paid	(53.18)	(56.72)
Net cash generated / (used in) financing activities (C)	(304.34)	(6,357.81)
Net increase in cash and cash equivalents (A+B+C)	63.37	82.11
Cash and cash equivalents at the beginning of the year	164.59	82.23
Effect of exchange rate changes on cash and cash equivalents	0.11	0.25
Cash and cash equivalents at the end of the year	228.07	164.59

See accompanying notes to the Statement of Consolidated Financial Results

Components of cash and cash equivalents

Particulars	As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
Cash and cash equivalents comprises of :		
a) Cash on hand	3.04	4.48
b) Balance with banks	224.83	159.87
c) Cash-in-transit / cheques in hand	0.20	0.24
Total	228.07	164.59

Aster DM Healthcare Limited

CIN : L85110TS2008PLC207383

Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Consolidated Cash Flows for the year ended 31 March 2026 (continued)

(Amount in INR crores)

Changes in financial liabilities arising from financing activities

Particulars	As at		Movement during the period					As at
	01 April 2025	Cash inflows	Cash outflows	Addition/ Modifications	Foreign exchange Movement	Non cash changes	Finance cost	31 March 2026
Borrowings (Current and Non-current) including interest	643.91		154.60	(193.20)	-	-	48.93	703.87
Lease liabilities	1,375.59		-	(131.17)	157.38	-	74.05	1,518.48
Total	2,019.50		154.60	(324.37)	157.38	-	122.98	2,222.35

Particulars	As at		Movement during the period					As at
	01 April 2024	Cash inflows	Cash outflows	Addition/ Modifications	Foreign exchange Movement	Non cash changes	Finance cost	31 March 2025
Borrowings (Current and Non-current) including interest	671.51		188.46	(273.40)	1.01	-	56.33	643.91
Lease liabilities	714.43		-	(114.45)	678.17	-	70.63	1,375.59
Total	1,385.94		188.46	(387.85)	679.18	-	126.96	2,019.50

Note : The above statement of cash flows has been prepared under the 'Indirect method' as set out in Ind AS 7, 'Statement of Cash Flows'.
See accompanying notes to the Statement of Consolidated Financial Results

Notes to the Statement of Consolidated Financial Results for the quarter and year ended 31 March 2026:

- The Statement of Consolidated Financial Results of Aster DM Healthcare Limited (the Parent Company/'Company') and its subsidiaries (together referred to as 'the Group'). DM Healthcare Employees Welfare Trust (the 'ESOP Trust') and its share of loss in associates for the quarter and year ended 31 March 2026 ('the Statement') has been reviewed by the Audit Committee on 29 April 2026 and approved by the Board of Directors on 30 April 2026. The statutory auditors, Deloitte Haskins & Sells, have expressed an unmodified review conclusion on the Consolidated Financial Results for the quarter ended 31 March 2026 and an unmodified audit opinion on the Consolidated Financial Results for the year ended 31 March 2026.
- 1) The Statement has been prepared in accordance with Indian Accounting Standards ('IndAS'), prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.
 - 2) During the year ended 31 March 2026, the Nomination and Remuneration Committee of the Parent Company approved grant of 507,500 options (exercise price ranging from INR 10.00 to INR 514.00) to the employees under the Aster DM Healthcare Limited Employees Stock Option Plan 2013.
 - 3) On 11 December 2025, the Parent Company submitted the Scheme of Amalgamation by way of merger of Quality Care India Limited (Transferor Company/QCIL) with Aster DM Healthcare Limited (Transferee Company) (the 'Applicant Companies') to the National Company Law Tribunal (NCLT) for approval of the said scheme. Subsequently, on 21 January 2026, the Parent Company received the Order from NCLT for convening the meetings of the Unsecured Trade Creditors and Equity Shareholders of the Applicant Companies during the period 27 February 2026 to 13 March 2026. Pursuant to this, the Company conducted its meetings on 10 March 2026 and obtained approval from the Equity Shareholders and Unsecured Trade Creditors with the requisite majority.
 - 4) The Group has presented the below items as Exceptional Items in the Statement :
 - i) The Group concluded the separation of its Gulf Cooperation Council (GCC) business on 3 April 2024. Pursuant to the sale, the Parent Company received a dividend of INR 5,569.96 crores from Affinity Holdings Private Limited ("Affinity"), its subsidiary in Mauritius. Consequent to this, the Parent Company has an obligation to incur CSR expenses amounting to INR 37.13 crores.
 - ii) On 21 November 2025, the Government of India notified the four Labour Codes ('the New Labour Codes') - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Group has assessed and disclosed the incremental impact of these changes on the basis of best available information, consistent with the New Labour Codes and the guidance provided by the Institute of Chartered Accountants of India. The incremental impact in the year consists of provision for gratuity amounting to INR 3.79 crores, provision for compensated absences amounting to INR 6.61 crores, provision for overtime allowance amounting to INR 1.35 crores, provision for fixed term employees amounting to INR 0.60 crores and provision for provident fund and employee state insurance amounting to INR 0.02 crores. This is primarily due to revision in wage definition. The Group continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the New Labour Codes and would make appropriate adjustments on the basis of such developments.
 - iii) On 23 April 2018, the Government of Kerala issued an order revising the minimum wages with retrospective effect from 1 October 2017. The Group had filed a writ petition (WP (C) No. 25109/2018) before the Hon'ble High Court of Kerala challenging the retrospective applicability of the order and failure to follow procedure for revision of rate of minimum wages under the Minimum Wages Act. The Hon'ble High Court of Kerala granted an interim stay and the matter is currently pending adjudication. On 6 March 2026, the Government of Kerala published a draft notification with respect to the minimum wages which superseded the old Notification issued in April 2018. Based on the above and legal advice obtained, Management believes that its position is likely to be upheld. Accordingly provision amounting to INR 38.40 crores with respect to above matter has been reversed.
 - iv) The Group incurred one-time expenses amounting to INR 21.61 crores towards professional fees relating to the merger, proposed acquisition and such other related costs.
 - 5) The Board of Directors at its meeting held on 26 March 2026 approved an interim dividend of INR 3 (par value of INR 10 each) per equity share. The same has been distributed to the shareholders of the Parent Company.
 - 6) The figures for the quarter ended 31 March 2026/31 March 2025 are balancing figures between the audited figures in respect of year ended 31 March 2026 / 31 March 2025 and the unaudited published figures in respect of nine months ended 31 December 2025 / 31 December 2024, which was subjected to limited review by the Statutory Auditors.
 - 7)

Aster DM Healthcare Limited
CIN : LR5110TS2008PLC207383

Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Amcerpet, Hyderabad, Telangana, India, 500038

Notes to the Statement of Consolidated Financial Results for the quarter and year ended 31 March 2026 (continued)

8) Segment details of Consolidated Financial Results for the quarter and year ended 31 March 2026

(Amount in INR crores)

Particulars	Quarter ended			Year ended	
	31 March 2026**	31 December 2025**	31 March 2025	31 March 2026**	31 March 2025*
	(Unaudited)			(Audited)	
1 Segment revenue					
Hospitals & Clinics	1,152.56	1,150.78	969.48	4,506.39	4,028.97
Labs	38.51	39.41	32.43	153.50	153.79
Wholesale Pharmacies*	19.77	28.48	25.77	108.32	158.49
Others	5.17	2.21	2.70	14.79	9.05
Total	1,216.01	1,220.89	1,030.37	4,783.00	4,350.30
Less: Inter-segment revenue	33.63	35.12	30.03	139.79	127.96
Revenue from operations	1,182.38	1,185.76	1,000.35	4,643.22	4,222.34
2 Segment results before tax, exceptional items and finance cost					
Hospitals & Clinics	206.82	183.75	146.80	780.42	644.81
Labs	3.98	5.07	0.30	14.84	3.37
Wholesale Pharmacies*	(0.36)	0.29	(0.63)	0.79	(1.76)
Others	(1.09)	(4.45)	(7.17)	(17.00)	(23.04)
Total	209.34	184.66	139.30	779.05	623.38
Adjustment :					
Finance cost	(29.99)	(31.46)	(32.43)	(122.98)	(126.96)
Share of loss of equity accounted investees	(8.53)	(8.75)	(10.01)	(37.00)	(18.91)
Other unallocable expenditure net of unallocable income (including adjustment of exceptional items)	(7.47)	(41.40)	(6.32)	(49.38)	(83.34)
Gain on disposal of business operations	-	-	-	-	5,148.09
Profit before tax from Continuing and Discontinued Operations	163.35	103.05	90.54	569.69	5,542.26
3 Segment assets					
Hospitals & Clinics**	6,711.99	6,500.61	5,007.53	6,711.99	5,007.53
Labs	83.34	59.63	54.68	83.34	54.68
Wholesale Pharmacies*	55.34	59.67	52.84	55.34	52.84
Others	26.62	26.03	34.41	26.62	34.41
Unallocated	1,234.67	1,248.32	1,456.92	1,234.67	1,456.92
Total	8,111.96	7,894.26	6,606.38	8,111.96	6,606.38
4 Segment liabilities					
Hospitals & Clinics	2,937.45	2,897.68	2,704.24	2,937.45	2,704.24
Labs	59.51	66.66	65.63	59.51	65.63
Wholesale Pharmacies*	8.75	19.36	23.51	8.75	23.51
Unallocated	272.55	80.40	161.55	272.55	161.55
Total	3,278.26	3,064.10	2,954.93	3,278.26	2,954.93

* includes retail pharmacies and opticals of Gulf Cooperation Council (GCC) business

** includes investment made in Quality Care India Limited amounting to INR 955.39 crores during the period ending 31 March 2026

Note - During the quarter, the Group revised its operating segments to align with CODM review. Clinics have been merged with Hospitals and Labs presented separately. Comparative figures have been reclassified accordingly.

Aster DM Healthcare Limited
CIN : L85110TS2008PLC207383

Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Amcerpet, Hyderabad, Telangana, India, 500038

Notes to the Statement of Consolidated Financial Results for the quarter and year ended 31 March 2026 (continued)

During the previous financial year, the Group announced the completion of the separation of its Gulf Cooperation Council ('GCC') business. As a result, the Group classified the GCC business as Discontinued Operations in the Statement.

- 9) Discontinued Operations include direct expenses, including transaction cost, clearly identifiable to the businesses being discontinued.
The impact of discontinued operations on income, expenses and tax is as under:

(Amount in INR crores)

Particulars	Quarter ended			Year ended	
	31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
	(Unaudited)			(Audited)	
Income					
Revenue from operations	-	-	-	-	83.88
Total income	-	-	-	-	83.88
Expenses					
Purchase of medicines and medical consumables	-	-	-	-	26.65
Professional fees to consultant doctors	-	-	-	-	11.61
Employee benefits expense	-	-	-	-	40.41
Finance costs	-	-	-	-	3.15
Depreciation and amortisation expenses	-	-	-	-	5.84
Other expenses	-	-	-	-	73.11
Total expenses	-	-	-	-	160.77
Loss before tax	-	-	-	-	(76.89)
Tax expense					
Current tax	-	-	-	-	-
Deferred tax	-	-	-	-	-
Total tax expense	-	-	-	-	-
Loss for the period/ year from discontinued operations	-	-	-	-	(76.89)
Gain on disposal of business operations	-	-	-	-	5,148.09
Profit after tax from discontinued operations	-	-	-	-	5,071.20

- 10) Statements of audited Standalone and Consolidated Financial Results are available for perusal at the website of the Parent Company and the stock exchanges.

For and on behalf of the Board of Directors of

Aster DM Healthcare Limited

CIN : L85110TS2008PLC207383

MANDAYAPU
RATH AZAD
MOOPEN

Digitally signed by
MANDAYAPURATH
AZAD MOOPEN
Date: 2026.04.30
15:27:52 +05'30'

Dr. Azad Moopen

Chairman and Executive Director

DIN 00159403

Dubai

30 April 2026

Aster DM Healthcare Limited
CIN : L85110TS2008PLC207383

Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Annexure A to statement of Unaudited Consolidated Financial Results for the quarter and year ended 31 March 2026

Sl No	Entity	Relationship	Country of incorporation
1	Aster DM Healthcare Limited	Parent	India
2	DM Med City Hospitals (India) Private Limited	Wholly owned Subsidiary	India
3	Ambady Infrastructure Private Limited	Wholly owned Subsidiary	India
4	Aster DM Multispecialty Hospital Private Limited (formerly known as Aster DM Healthcare (Trivandrum) Private Limited)	Wholly owned Subsidiary	India
5	Sri Sainatha Multispecialty Hospitals Private Limited	Wholly owned Subsidiary	India
6	Aster Clinical Lab LLP	Wholly owned Subsidiary	India
7	Aster DM Super-Specialty Hospital (Sarjapur) Private Limited	Wholly owned Subsidiary (w.e.f. July 21, 2025)	India
8	Aster DM Super-Specialty Hospital (Yeswanthpur) Private Limited	Wholly owned Subsidiary (w.e.f. July 28, 2025)	India
9	DM Healthcare Employees Welfare Trust	Trust	India
10	Affinity Holdings Private Limited	Wholly owned Subsidiary	Mauritius
11	Malabar Institute of Medical Sciences Limited	Subsidiary	India
12	Dr. Ramesh Cardiac and Multispecialty Hospitals Private Limited	Subsidiary	India
13	Prerana Hospital Limited	Subsidiary	India
14	Hindustan Pharma Distributors Private Limited	Subsidiary	India
15	EMED Human Resources India Private Limited	Step down Subsidiary	India
16	Ezhimala Infrastructure LLP	Step down Subsidiary	India
17	Warseps Healthcare LLP	Step down Subsidiary	India
18	Sanghamitra Hospitals Private Limited	Step down Subsidiary	India
19	Aster Ramesh Duhita LLP	Step down Subsidiary	India
20	Komali Fertility Centre LLP	Step down Subsidiary	India
21	Komali Fertility Centre LLP Ongole	Step down Subsidiary	India
22	Adiran IB Healthcare Private Limited	Step down Subsidiary	India
23	Cantown Infra Developers LLP	Step down Subsidiary	India
24	Aasraya Healthcare LLP	Step down Subsidiary	India
25	MIMS Infrastructure and Properties Private Limited	Associate	India
26	Alfaone Medicals Private Limited	Associate	India
27	Alfaone Retail Pharmacies Private Limited	Associate	India
28	Mindriot Research and Innovation Foundation	Associate	India